Last reviewed · How we verify
NCT01472146
Phase II Clinical Trial of Neoadjuvant Treatment With Zolendronic Acid Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Phase 2 trial testing Zo-Nantax in Breast Cancer in 58 participants. Completed in 1 May 2017.
1 July 2016
Quick facts
| Lead sponsor | Susanne Crocamo |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 58 |
| Start date | 1 October 2011 |
| Primary completion | 1 July 2016 |
| Estimated completion | 1 May 2017 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Zo-Nantax — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Disease — all drugs for Breast Disease →
- Neoplasms — all drugs for Neoplasms →
- Neoplasms by Site — all drugs for Neoplasms by Site →
Sponsor
Susanne Crocamo — full company profile →
Who can join
Adults 18 to 75, female only, with Breast Cancer or Breast Disease. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Evaluate the residual cancer burden (RCB)
Time frame: 6 months
Use MD Anderson calculator to quantify the minimal residual disease
Sponsor's own description
The purpose of this study is to evaluate the association of zoledronic acid with standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER 2 positive.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.
Crocamo S, Binato R, de Paula B, Vignal G, et al · · 2019 · cited 8× · PMID 31210800 · DOI 10.1177/1758835919853971 -
Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.
de Paula B, Abdelhay E, de Sousa CAM, Crocamo S. · · 2024 · cited 1× · PMID 38911562 · DOI 10.21037/atm-23-1880
Verify or expand the search:
- PubMed search for NCT01472146
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01472146 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Susanne Crocamo
- Last refreshed: 4 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01472146.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing